title: Interferon administered intralesionally in skin and oral cavity lesions in heterosexual drug addicted patients with AIDS-related Kaposi's sarcoma.
authors.forename: E
authors.initials: E
authors.lastname: Sulis
authors.forename: C
authors.initials: C
authors.lastname: Floris
authors.forename: M L
authors.initials: ML
authors.lastname: Sulis
authors.forename: S
authors.initials: S
authors.lastname: Zurrida
authors.forename: S
authors.initials: S
authors.lastname: Piro
authors.forename: A
authors.initials: A
authors.lastname: Pintus
authors.forename: L
authors.initials: L
authors.lastname: Contu
mesh_terms: D000163:Acquired Immunodeficiency Syndrome / Q000150:complications; D000328:Adult; D006801:Humans; D007370:Interferon Type I / Q000008:administration & dosage*; D000077190:Interferon alpha-2; D016898:Interferon-alpha / Q000008:administration & dosage* / Q000627:therapeutic use; D008297:Male; D009062:Mouth Neoplasms / Q000628:therapy*; D011994:Recombinant Proteins; D012514:Sarcoma, Kaposi / Q000209:etiology / Q000628:therapy*; D012878:Skin Neoplasms / Q000628:therapy*; D019966:Substance-Related Disorders
chemical_list: D007370:Interferon Type I; D000077190:Interferon alpha-2; D016898:Interferon-alpha; D011994:Recombinant Proteins